These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29509992)

  • 1. Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease.
    Chaudhury CS; Purdy JB; Liu CY; Morse CG; Stanley TL; Kleiner D; Hadigan C
    Liver Int; 2018 May; 38(5):797-802. PubMed ID: 29509992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
    Pizarro M; Solís N; Quintero P; Barrera F; Cabrera D; Rojas-de Santiago P; Arab JP; Padilla O; Roa JC; Moshage H; Wree A; Inzaugarat E; Feldstein AE; Fardella CE; Baudrand R; Riquelme A; Arrese M
    Liver Int; 2015 Sep; 35(9):2129-38. PubMed ID: 25646700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
    J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.
    Hui SCN; So HK; Chan DFY; Wong SKH; Yeung DKW; Ng EKW; Chu WCW
    Eur J Radiol; 2018 Oct; 107():7-13. PubMed ID: 30292275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet.
    Wada T; Miyashita Y; Sasaki M; Aruga Y; Nakamura Y; Ishii Y; Sasahara M; Kanasaki K; Kitada M; Koya D; Shimano H; Tsuneki H; Sasaoka T
    Am J Physiol Endocrinol Metab; 2013 Dec; 305(11):E1415-25. PubMed ID: 24129399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial).
    Johansen ML; Schou M; Rossignol P; Holm MR; Rasmussen J; Brandt N; Frandsen M; Chabanova E; Dela F; Faber J; Kistorp C
    Diabetes Obes Metab; 2019 Oct; 21(10):2305-2314. PubMed ID: 31183945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.
    Matthews L; Kleiner DE; Chairez C; McManus M; Nettles MJ; Zemanick K; Morse CG; Benator D; Kovacs JA; Hadigan C
    AIDS Res Hum Retroviruses; 2015 Oct; 31(10):961-6. PubMed ID: 26214341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet.
    Shidfar F; Bahrololumi SS; Doaei S; Mohammadzadeh A; Gholamalizadeh M; Mohammadimanesh A
    Can J Gastroenterol Hepatol; 2018; 2018():1053710. PubMed ID: 29850450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design.
    Stone IB; Green JAEM; Koefoed AW; Hornik ES; Williams JS; Adler GK; Williams GH
    Pharmacogenet Genomics; 2021 Jun; 31(4):83-88. PubMed ID: 33904521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV.
    Srinivasa S; Fitch KV; Wong K; O'Malley TK; Maehler P; Branch KL; Looby SE; Burdo TH; Martinez-Salazar EL; Torriani M; Lyons SH; Weiss J; Feldpausch M; Stanley TL; Adler GK; Grinspoon SK
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2376-2384. PubMed ID: 29659888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
    Polyzos SA; Kountouras J; Mantzoros CS; Polymerou V; Katsinelos P
    Diabetes Obes Metab; 2017 Dec; 19(12):1805-1809. PubMed ID: 28452101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
    Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
    Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
    Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.
    Raman SV; Hor KN; Mazur W; Cardona A; He X; Halnon N; Markham L; Soslow JH; Puchalski MD; Auerbach SR; Truong U; Smart S; McCarthy B; Saeed IM; Statland JM; Kissel JT; Cripe LH
    J Am Heart Assoc; 2019 Oct; 8(19):e013501. PubMed ID: 31549577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats.
    Taye A; Abdel-Raheem IT
    Ann Hepatol; 2012; 11(3):384-91. PubMed ID: 22481458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique.
    Lin SC; Heba E; Wolfson T; Ang B; Gamst A; Han A; Erdman JW; O'Brien WD; Andre MP; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1337-1345.e6. PubMed ID: 25478922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage.
    Di Costanzo A; D'Erasmo L; Polimeni L; Baratta F; Coletta P; Di Martino M; Loffredo L; Perri L; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Catalano C; Maranghi M; Del Ben M; Angelico F; Arca M
    Atherosclerosis; 2017 Feb; 257():232-239. PubMed ID: 28027788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of a three-step magnetic resonance imaging approach for the assessment of hepatic steatosis in an asymptomatic study population.
    Hetterich H; Bayerl C; Peters A; Heier M; Linkohr B; Meisinger C; Auweter S; Kannengießer SA; Kramer H; Ertl-Wagner B; Bamberg F
    Eur Radiol; 2016 Jun; 26(6):1895-904. PubMed ID: 26340812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.